Get the Stockscreener App
6.65
4.07%
0.26
Unicycive Therapeutics Inc stock is traded at $6.65, with a volume of 484.49K.
It is up +4.07% in the last 24 hours and down -0.89% over the past month.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.
See More
Previous Close:
$6.39
Open:
$6.51
24h Volume:
484.49K
Relative Volume:
0.94
Market Cap:
$142.92M
Revenue:
$675.00K
Net Income/Loss:
$-33.47M
P/E Ratio:
-2.3769
EPS:
-2.7978
Net Cash Flow:
$-29.88M
1W Performance:
-1.63%
1M Performance:
-0.89%
6M Performance:
+77.81%
1Y Performance:
+946.26%
1-Day Range:
$6.48
$6.87
1-Week Range:
$6.31
$6.92
52-Week Range:
$0.45
$8.2457
Unicycive Therapeutics Inc Stock (UNCY) Company Profile
Name
Unicycive Therapeutics Inc
Sector
Industry
Phone
650-384-0642
Address
4300 EL CAMINO REAL, SUITE 210, LOS ALTOS
Compare UNCY vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
UNCY
Unicycive Therapeutics Inc
|
6.65 | 137.33M | 675.00K | -33.47M | -29.88M | -2.7978 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Unicycive Therapeutics Inc Stock (UNCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-25 | Initiated | Guggenheim | Buy |
| Apr-04-24 | Initiated | Piper Sandler | Overweight |
Unicycive Therapeutics Inc Stock (UNCY) Latest News
Unicycive Therapeutics (UNCY) Stock Analysis Report | Financials & Insights - Benzinga Japan
Portfolio Recap: Is Unicycive Therapeutics Inc stock risky to hold nowEarnings Summary Report & Daily Chart Pattern Signal Reports - baoquankhu1.vn
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Unicycive Therapeutics (UNCY) to Release Quarterly Earnings on Monday - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect - ACCESS Newswire
Pullback Watch: Is Unicycive Therapeutics Inc a potential multi baggerQuarterly Earnings Report & Risk Managed Trade Strategies - baoquankhu1.vn
Stop Loss: Why is Unicycive Therapeutics Inc stock going down2026 Price Action Summary & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
If You Invested $1,000 in Unicycive Therapeutics Inc (UNCY) - Stock Titan
Unicycive Therapeutics Company Profile & Introduction - Moomoo
UNCY Technical Analysis & Stock Price Forecast - Intellectia AI
UNCY Stock Price, Quote & Chart | UNICYCIVE THERAPEUTICS INC (NASDAQ:UNCY) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Important Notice to Long-Term Shareholders of ASP Isotopes - GlobeNewswire
Important Notice to Long-Term Shareholders of ASP Isotopes Inc. (NASDAQ: ASPI); Integer Holdings Corp. (NYSE: ITGR): Soleno Therapeutics, Inc. (NASDAQ: SLNO); and Unicycive Therapeutics, Inc. (NASDAQ: UNCY): Grabar Law Office is Investigating Claims on Your Behalf - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out - ACCESS Newswire
Notice to Long-Term Shareholders of ASP Isotopes Inc. - GlobeNewswire
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Connect - ACCESS Newswire
Unicycive Therapeutics (NASDAQ:UNCY) Shares Down 0.4%Here's Why - MarketBeat
Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Important Notice to Long-Term Shareholders of Integer Holdings Corp. (NYSE: ITGR): Molina Healthcare, Inc. (NYSE: MOH); Unicycive Therapeutics, Inc. (NASDAQ: UNCY); and WEBTOON Entertainment Inc. (NASDAQ: WBTN): Grabar Law Office Investigates - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
Important Notice to Long-Term Shareholders of Boston - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Encourages Unicycive Therapeutics, Inc. (UNCY) Investors to Inquire about Securities Investigation - ACCESS Newswire
Unicycive Therapeutics (UNCY) price target decreased by 12.88% to 47.43 - MSN
Aug Setups: Is Unicycive Therapeutics Inc on track to beat earningsTrade Volume Report & Fast Gain Stock Tips - baoquankhu1.vn
Kuehn Law Encourages Investors of Unicycive Therapeutics, Inc. to Contact Law Firm - TMX Newsfile
Unicycive Therapeutics : March 2026 Corporate Presentation - marketscreener.com
Important Notice to Long-Term Shareholders of Corcept - GlobeNewswire
UNCY Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Piper Sandler Remains a Buy on Unicycive Therapeutics (UNCY) - The Globe and Mail
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Shareholders to Reach Out - ACCESS Newswire
UNCY Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Can Unicycive's OLC Address Hyperphosphatemia's Unmet Need With Its 3P Advantage? - RTTNews
Unicycive’s Kidney Drug Pipeline Puts A Small Stock On The Clock - Finimize
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Unicycive Therapeutics, Inc. (UNCY) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Will Unicycive Therapeutics Inc. benefit from current market trendsJuly 2025 Snapshot & Verified Entry Point Signals - mfd.ru
Unicycive Therapeutics (UNCY) Gets a Buy from Westpark Capital - The Globe and Mail
Why is Unicycive Therapeutics Inc. stock going downJuly 2025 Spike Watch & Comprehensive Market Scan Insights - mfd.ru
2026-02-19 | Unicycive Therapeutics, Inc. (UNCY) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:UNCY | Press Release - Stockhouse
Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Unicycive Therapeutics (NASDAQ:UNCY) Stock Price Up 2.4%Should You Buy? - MarketBeat
2026-02-17 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Unicycive Therapeutics, Inc. (UNCY) And Encourages Investors to Connect | NDAQ:UNCY | Press Release - Stockhouse
Important Notice to Long-Term Shareholders of Unicycive Therapeutics, Inc. (UNCY): Grabar Law Office Is Investigating Claims on Your Behalf - marketscreener.com
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Will Unicycive Therapeutics Inc. stock go up in YEAR2025 Trade Ideas & Safe Entry Zone Tips - mfd.ru
UNCY Should I Buy - Intellectia AI
2026-02-12 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Unicycive Therapeutics, Inc. (UNCY) And Encourages Stockholders to Reach Out | NDAQ:UNCY | Press Release - Stockhouse
The Hyperphosphatemia Market was valued at approximately USD 4 billion in 2023, according to DelveInsight - Barchart.com
Unicycive Therapeutics: Speculative Biotech Stock Whipsaws Traders As Wall Street Stays Cautious - AD HOC NEWS
Investor Mood: Is Open Lending Corporation stock a top performer YTDWatch List & Technical Buy Zone Confirmations - baoquankhu1.vn
Unicycive Therapeutics Inc Stock (UNCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):